Cargando…
A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) we...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589165/ https://www.ncbi.nlm.nih.gov/pubmed/34767586 http://dx.doi.org/10.1371/journal.pone.0259093 |
_version_ | 1784598637914882048 |
---|---|
author | Athanasiou, Alcibiade Tennstedt, Pierre Wittig, Anja Huber, Ramy Straub, Oliver Schiess, Ralph Steuber, Thomas |
author_facet | Athanasiou, Alcibiade Tennstedt, Pierre Wittig, Anja Huber, Ramy Straub, Oliver Schiess, Ralph Steuber, Thomas |
author_sort | Athanasiou, Alcibiade |
collection | PubMed |
description | The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) were used for analysis. Clinical Grade Group and clinical stage was determined using biopsy samples while tumor marker concentrations were measured in serum using immunoassays. The prognostic utility of the proposed marker combination was assessed using Cox proportional hazard regression and Kaplan-Meier analysis. The performance was compared to the Cancer of the Prostate Risk Assessment (CAPRA) score in the overall cohort and in a low-risk patient subset. A multivariable model comprising fibronectin 1, galectin-3-binding protein, lumican, matrix metalloprotease 9, thrombospondin-1 and PSA together with clinical Grade Group (GG) and clinical stage (cT) was created. The proposed model was a significant predictor of biochemical recurrence (BCR) (HR 1.29 per 5 units score, 95%CI 1.20–1.38, p<0.001). The Kaplan-Meier analysis showed that the proposed model had a better prediction for low-risk disease after RP compared to CAPRA (respectively 5.0% vs. 9.1% chance of BCR). In a pre-defined low risk population subset, the risk of BCR using the proposed model was below 5.2% and thus lower when compared to CAPRA = 0–2 (9%), GG<2 (7%) and NCCN = low-risk (6%) subsets. Additionally, the proposed model could significantly (p<0.001) discriminate patients with adverse pathology (AP) events at RP from those without. In conclusion, the proposed model is superior to CAPRA for the prediction of BCR after RP in the overall cohort as well as a in a pre-defined low risk patient population subset. It is also significantly associated with AP at RP. |
format | Online Article Text |
id | pubmed-8589165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-85891652021-11-13 A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology Athanasiou, Alcibiade Tennstedt, Pierre Wittig, Anja Huber, Ramy Straub, Oliver Schiess, Ralph Steuber, Thomas PLoS One Research Article The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) were used for analysis. Clinical Grade Group and clinical stage was determined using biopsy samples while tumor marker concentrations were measured in serum using immunoassays. The prognostic utility of the proposed marker combination was assessed using Cox proportional hazard regression and Kaplan-Meier analysis. The performance was compared to the Cancer of the Prostate Risk Assessment (CAPRA) score in the overall cohort and in a low-risk patient subset. A multivariable model comprising fibronectin 1, galectin-3-binding protein, lumican, matrix metalloprotease 9, thrombospondin-1 and PSA together with clinical Grade Group (GG) and clinical stage (cT) was created. The proposed model was a significant predictor of biochemical recurrence (BCR) (HR 1.29 per 5 units score, 95%CI 1.20–1.38, p<0.001). The Kaplan-Meier analysis showed that the proposed model had a better prediction for low-risk disease after RP compared to CAPRA (respectively 5.0% vs. 9.1% chance of BCR). In a pre-defined low risk population subset, the risk of BCR using the proposed model was below 5.2% and thus lower when compared to CAPRA = 0–2 (9%), GG<2 (7%) and NCCN = low-risk (6%) subsets. Additionally, the proposed model could significantly (p<0.001) discriminate patients with adverse pathology (AP) events at RP from those without. In conclusion, the proposed model is superior to CAPRA for the prediction of BCR after RP in the overall cohort as well as a in a pre-defined low risk patient population subset. It is also significantly associated with AP at RP. Public Library of Science 2021-11-12 /pmc/articles/PMC8589165/ /pubmed/34767586 http://dx.doi.org/10.1371/journal.pone.0259093 Text en © 2021 Athanasiou et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Athanasiou, Alcibiade Tennstedt, Pierre Wittig, Anja Huber, Ramy Straub, Oliver Schiess, Ralph Steuber, Thomas A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology |
title | A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology |
title_full | A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology |
title_fullStr | A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology |
title_full_unstemmed | A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology |
title_short | A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology |
title_sort | novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589165/ https://www.ncbi.nlm.nih.gov/pubmed/34767586 http://dx.doi.org/10.1371/journal.pone.0259093 |
work_keys_str_mv | AT athanasioualcibiade anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT tennstedtpierre anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT wittiganja anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT huberramy anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT strauboliver anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT schiessralph anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT steuberthomas anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT athanasioualcibiade novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT tennstedtpierre novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT wittiganja novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT huberramy novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT strauboliver novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT schiessralph novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT steuberthomas novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology |